Class Action Lawsuit Filed Against Intellia Therapeutics, Inc

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ: NTLA). Such investors are advised to contact Danielle Peyton at email@example.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Intellia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until April 14, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Intellia securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

Click here for information about joining the class action

On January 9, 2025, Intellia issued a press release "announc[ing] its strategic priorities and key anticipated 2025 milestones". Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the Company cutting around 27% of its workforce. Intellia said that it expects to incur charges of approximately $8 million in the first quarter of 2025 in connection with the restructuring. Intellia further announced the retirement of its Chief Scientific Officer, Laura Sepp-Lorenzino, Ph.D.

On this news, Intellia's stock price fell $1.82 per share, or 15.14%, to close at $10.20 per share on January 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
email@example.com
646-581-9980 ext. 7980